General Information of Drug (ID: DMNJEGV)

Drug Name
PBGM01 Drug Info
Indication
Disease Entry ICD 11 Status REF
GM1 gangliosidosis 5C56.00 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMNJEGV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug(s) Targeting Beta-galactosidase (GLB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AXO-AAV-GM1 DMFBMI7 GM1 gangliosidosis 5C56.00 Phase 1/2 [3]
LYS-GM-101 DMPD79C GM1 gangliosidosis 5C56.00 Phase 1/2 [4]
5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin DM7RHOC GM1 gangliosidosis 5C56.00 Preclinical [5]
N-Octyl-4-epi-beta-valienamine DMTQ2UD GM1 gangliosidosis 5C56.00 Preclinical [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Beta-galactosidase (GLB1) TTNGJPH BGAL_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04713475) Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered Into the Cisterna Magna of Pediatric Type 1 (Early Onset) and Type 2a (Late Onset) Infantile GM1 Gangliosidosis. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Passage Bio
3 Clinical pipeline report, company report or official report of Axovant Gene Therapies
4 ClinicalTrials.gov (NCT04273269) An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human beta-Galactosidase cDNA for Treatment of GM1 Gangliosidosis. U.S.National Institutes of Health.
5 A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013 Mar;21(3):526-32.
6 Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72.